Xeris Biopharma Holdings, Inc. 8-K

What Happened
Xeris Biopharma Holdings, Inc. announced on May 7, 2026 that it furnished a press release reporting its results of operations and business highlights for the three months ended March 31, 2026. The company submitted that press release as Exhibit 99.1 to its Form 8-K; the report was signed by CFO Steven M. Pieper.

Key Details

• Filing date: May 7, 2026 (Form 8-K).
• Period covered: three months ended March 31, 2026 (Q1 2026).
• Exhibit furnished: 99.1 — press release dated May 7, 2026.
• Exhibit 104: Cover Page Interactive Data File (Inline XBRL) included.
• Executed and signed by Steven M. Pieper, Chief Financial Officer.

Why It Matters
This 8-K tells investors that Xeris has publicly released its quarterly operating results and business highlights; those specifics (revenue, net income/loss, guidance, operational updates) will be in the press release and supporting filings. The press release is furnished (not “filed”), which provides the company’s update to the market but has different disclosure liabilities under SEC rules. Investors should review Exhibit 99.1 and any related quarterly filings (e.g., 10-Q) for the detailed financial figures and metrics before making investment decisions.